As previously reported, William Blair analyst Myles Minter upgraded Intellia Therapeutics (NTLA) to Outperform from Market Perform after the company announced that the FDA lifted the clinical hold on the Phase 3 MAGNITUDE study of its TTR silencing gene editing therapy nexiguran ziclumeran for the treatment of ATTR-cardiomyopathy. The firm view today’s clinical hold lift as “a major win for Intellia” and cites increased line of sight for nex-z in ATTR-CM, which it views as “a large market,” for its upgrade.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics upgraded to Outperform from Market Perform at William Blair
- Intellia Resumes Key Trial and Expands ATM Program
- Intellia announces FDA lift of clinical hold on MAGNITUDE Phase 3 trial
- Intellia Therapeutics Eyes 2026 Pivotal CRISPR Milestone
- Intellia Therapeutics reports Q4 EPS (83c), consensus (96c)